MedVasc secures €2.2M financing and advances its Solutio toward FDA clearance
Lund-based MedVasc has announced they have successfully completed production and testing activities in accordance with its plan. In parallel, the company closed a new financing round at the end of 2025, raising € 2.2 million (SEK 24 million) from existing shareholders.
With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026.
”The strong participation from current owners demonstrates continued confidence in MedVasc’s strategy, execution capability, and long-term value creation. The board and management view this support as a clear validation of the company’s direction and its ongoing development efforts,”
says Cathrin Johansson, CEO of MedVasc
Solutio is developed to provide painless and precise local anesthesia during thermal treatment of venous insufficiency. The anesthesia catheter is compatible with so-called gold standard treatment fibers (RF/Laser) worldwide.
The post MedVasc secures €2.2M financing and advances its Solutio toward FDA clearance appeared first on Øresund Startups.